TRDA
Entrada Therapeutics Inc
6.20$
-4.3%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -56.0% | -9.6% | -43.2% | 42.1% | -124.0% | -84.5% | -187.3% | -1,512.3% | -1,754.2% | -2,479.1% | -4,765.1% | -3,615.0% | -2,874.0% | |
| 1.9% | 1.8% | 1.6% | 1.0% | 4.8% | 2.7% | 4.6% | 53.0% | 76.2% | -214.4% | 92.0% | 93.7% | 1.9% | |
| 7.8% | 9.2% | 6.3% | 4.9% | 24.8% | 12.6% | 24.7% | 258.9% | 317.0% | 335.5% | 542.2% | 573.5% | 413.3% | |
| -142.5% | 7.1% | -87.4% | -19.5% | -65.5% | -96.1% | -125.8% | 435.5% | 632.8% | 180.9% | -797.6% | 530.0% | 220.7% | |
| 3.3% | 2.3% | 1.4% | 1.1% | 3.3% | 1.7% | 5.6% | 14.1% | 10.6% | 15.9% | 5.0% | 1.2% | 9.2% | |
| -8.5% | 45.5% | 44.2% | -25.7% | -423.7% | 142.7% | 23.3% | 1,733.2% | 3,042.7% | 2,241.6% | 3,084.2% | 6,119.0% | 3,417.9% | |
| – | 1.1% | – | – | 1.3% | – | – | 16.3% | – | 11.2% | – | 35.6% | – | |
| 0.8% | 1.6% | 0.3% | 107.0% | -0.1% | 3.7% | 1.7% | 17.3% | 0.5% | 14.8% | 11.4% | 39.0% | 13.9% | |
| -63.7% | 37.6% | 1.4% | 123.4% | -547.8% | 61.9% | -162.3% | 238.2% | 1,289.0% | -222.6% | -1,669.5% | 2,543.0% | 557.8% | |
| -59.3% | -11.9% | -44.6% | 41.0% | -127.3% | -86.2% | -192.9% | -1,526.4% | -1,743.6% | -2,463.1% | -4,770.2% | -3,616.3% | -2,867.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.